Elicio Therapeutics Advances ELI-002 and Secures Funding

Elicio Therapeutics, a clinical-stage biotechnology company, has made significant strides in advancing its lead product candidate, ELI-002, and securing funding to support its development. ELI-002 is an off-the-shelf cancer vaccine targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. The company's innovative Amphiphile (AMP) technology aims to enhance the education, activation, and amplification of cancer-specific T cells, promoting durable cancer immunosurveillance in patients.

Elicio Therapeutics recently presented updated preliminary results from the ongoing AMPLIFY-7P Phase 1 clinical trial of ELI-002 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The data demonstrated durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens. The magnitude of T cell response correlated with disease-free survival (DFS), with the highest three quartiles of responders not yet reaching mDFS compared to the lowest quartile, which achieved a mDFS of 3.1 months (p=0.0027). Additionally, antigen spreading was observed in 100% of RP2D-treated patients, suggesting ELI-002-induced tumor immunosurveillance to personalized tumor neoantigens beyond mKRAS.



The success of ELI-002 in clinical trials has bolstered investor confidence in Elicio Therapeutics' innovative approach to cancer immunotherapy. The company has secured funding to support the development of ELI-002 and its pipeline of additional off-the-shelf therapeutic cancer vaccines, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

Elicio Therapeutics' innovative Amphiphile (AMP) technology sets it apart from traditional cancer vaccines by targeting lymph nodes, where immune cells reside, rather than relying on systemic administration. This targeted approach enhances the action of key immune cells, generating a robust, tumor-specific immune response. The success of ELI-002 in clinical trials, with durable T cell responses and correlations with disease-free survival, has instilled confidence in investors, leading to increased interest and funding for the company.

In conclusion, Elicio Therapeutics' advancements in ELI-002 and the securing of funding demonstrate the company's potential in the cancer immunotherapy space. The company's innovative Amphiphile (AMP) technology and the promising results from clinical trials have attracted investors and positioned Elicio Therapeutics as a leader in the development of novel immunotherapies for the treatment of cancer. As the company continues to advance its pipeline, it is well-positioned to capitalize on the growing demand for effective and off-the-shelf cancer vaccines.